These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8630727)

  • 41. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice.
    Schönbeck U; Sukhova GK; Shimizu K; Mach F; Libby P
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7458-63. PubMed ID: 10861012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells.
    Baccam M; Bishop GA
    Eur J Immunol; 1999 Dec; 29(12):3855-66. PubMed ID: 10601993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blocking T-cell costimulation to prevent transplant rejection.
    Zheng XG; Turka LA
    Transplant Proc; 1998 Aug; 30(5):2146-9. PubMed ID: 9723421
    [No Abstract]   [Full Text] [Related]  

  • 44. Activation of bovine B cells via surface immunoglobulin M cross-linking or CD40 ligation results in different B-cell phenotypes.
    Haas KM; Estes DM
    Immunology; 2000 Feb; 99(2):272-8. PubMed ID: 10692047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody.
    Markees TG; Phillips NE; Gordon EJ; Noelle RJ; Maliszewski C; Mordes JP; Greiner DL; Rossini AA
    Transplant Proc; 1999; 31(1-2):884-5. PubMed ID: 10083387
    [No Abstract]   [Full Text] [Related]  

  • 46. T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro.
    Vecchiarelli A; Retini C; Pietrella D; Monari C; Kozel TR
    Eur J Immunol; 2000 May; 30(5):1385-93. PubMed ID: 10820385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.
    Cerutti A; Schaffer A; Goodwin RG; Shah S; Zan H; Ely S; Casali P
    J Immunol; 2000 Jul; 165(2):786-94. PubMed ID: 10878352
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.
    Durie FH; Fava RA; Foy TM; Aruffo A; Ledbetter JA; Noelle RJ
    Science; 1993 Sep; 261(5126):1328-30. PubMed ID: 7689748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contribution of CD40-CD154-mediated costimulation to an alloresponse in vivo.
    Förster E; Krenger W; Joergensen J; Hof R; Geha RS; Holländer GA
    Transplantation; 1999 May; 67(9):1284-7. PubMed ID: 10342324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.
    Larsen CP; Alexander DZ; Hollenbaugh D; Elwood ET; Ritchie SC; Aruffo A; Hendrix R; Pearson TC
    Transplantation; 1996 Jan; 61(1):4-9. PubMed ID: 8560571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The expansive role of CD40 and its ligand, gp39, in immunity.
    Foy TM; Durie FH; Noelle RJ
    Semin Immunol; 1994 Oct; 6(5):259-66. PubMed ID: 7532456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells.
    Eck SC; Turka LA
    Cancer Immunol Immunother; 1999 Sep; 48(6):336-41. PubMed ID: 10473809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning.
    Durham MM; Bingaman AW; Adams AB; Ha J; Waitze SY; Pearson TC; Larsen CP
    J Immunol; 2000 Jul; 165(1):1-4. PubMed ID: 10861026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High sequence homology between human and pig CD40 with conserved binding to human CD154.
    Rushworth SA; Bravery CA; Thompson S
    Transplantation; 2000 Mar; 69(5):936-40. PubMed ID: 10755553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.
    Funakoshi S; Taub DD; Asai O; Hirano A; Ruscetti FW; Longo DL; Murphy WJ
    Leuk Lymphoma; 1997 Jan; 24(3-4):187-99. PubMed ID: 9156649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor.
    Kalinichenko TV; Mokyr MB
    Cancer Immunol Immunother; 1998 Aug; 46(6):293-303. PubMed ID: 9756413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes.
    Kotowicz K; Dixon GL; Klein NJ; Peters MJ; Callard RE
    Immunology; 2000 Aug; 100(4):441-8. PubMed ID: 10929070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.
    Terheyden P; Straten P; Bröcker EB; Kämpgen E; Becker JC
    J Immunol; 2000 Jun; 164(12):6633-9. PubMed ID: 10843723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of CD40-CD40-ligand interaction in Ig-isotype switching.
    Fuleihan R; Ramesh N; Geha RS
    Curr Opin Immunol; 1993 Dec; 5(6):963-7. PubMed ID: 7507684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.